PMID- 30084800
OWN - NLM
STAT- MEDLINE
DCOM- 20181029
LR  - 20181029
IS  - 1165-158X (Electronic)
IS  - 0145-5680 (Linking)
VI  - 64
IP  - 10
DP  - 2018 Jul 30
TI  - Sensitization of cisplatin resistant bladder tumor by combination of cisplatin 
      treatment and co-culture of dendritic cells with apoptotic bladder cancer cells.
PG  - 102-107
AB  - Dendritic cells (DCs) are a population of professional antigen presenting cells 
      (APCs), serving as central regulators of adaptive immunity by presenting 
      antigens. In addition, DCs play essential roles in the connection of the innate 
      and adaptive immune responses. Recently, therapeutic vaccines turn out to become 
      a viable therapeutic approach for immunotherapy of cancers. Here we report a 
      dendritic cell-based vaccine strategy which could suppress the bladder tumor 
      growth in vivo and improve the efficiency of chemotherapy. In this study, we 
      investigate the antitumor effects of mature DCs induced by antigen loading in 
      bladder tumor in vivo. We demonstrate the co-culture of cisplatin induced 
      apoptotic human bladder cancer cell line, T24 cells with immature DCs could 
      promote the maturation of DCs. Cisplatin and these activated DCs were 
      reintroduced into mice bearing the T24 cisplatin resistant cells-derived tumor 
      growth to activate or boost the immune response. Mice with iDCs co-cultured with 
      apoptotic T24 (iDCs T24 Apo) cells injection effectively initiate a cytotoxic 
      effect against tumor growth and improve the survival rates of mice compared with 
      controls. Moreover, we observed injection of iDCs T24 apoptosis cells combined 
      with cisplatin into mice with T24 cisplatin resistant cancer cells-derived tumor 
      resulted in a statistically significant suppression of tumor growth compared with 
      mice injected with PBS alone, cisplatin alone, iDCs, iDCs T24 Apo cells, 
      cisplatin plus iDCs. This study provides a dendritic cell-based vaccine strategy 
      which might reduce the risk of tumor recurrence and improve the efficiency of 
      anti-chemoresistance of bladder cancer.
FAU - Zhang, Qi
AU  - Zhang Q
AD  - Department of Physical Examination, Jinshan Hospital, Fudan University, Shanghai 
      201508, China.
FAU - Chen, Zhuo
AU  - Chen Z
AD  - Department of Urology, Jinshan Hospital, Fudan University, Shanghai 201508, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20180730
PL  - France
TA  - Cell Mol Biol (Noisy-le-grand)
JT  - Cellular and molecular biology (Noisy-le-Grand, France)
JID - 9216789
RN  - 0 (Antineoplastic Agents)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*therapeutic use
MH  - Apoptosis/drug effects
MH  - Cell Line, Tumor
MH  - Cells, Cultured
MH  - Cisplatin/*therapeutic use
MH  - Coculture Techniques
MH  - Dendritic Cells/immunology/*transplantation
MH  - Drug Resistance, Neoplasm
MH  - Humans
MH  - Immunotherapy
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - T-Lymphocytes/immunology
MH  - Urinary Bladder/drug effects/immunology
MH  - Urinary Bladder Neoplasms/immunology/*therapy
OTO - NOTNLM
OT  - Bladder tumor
OT  - Cisplatin
OT  - Dendritic cells
OT  - Immunotherapy.
EDAT- 2018/08/08 06:00
MHDA- 2018/10/30 06:00
CRDT- 2018/08/08 06:00
PHST- 2017/05/12 00:00 [received]
PHST- 2018/03/02 00:00 [accepted]
PHST- 2018/05/21 00:00 [revised]
PHST- 2018/08/08 06:00 [entrez]
PHST- 2018/08/08 06:00 [pubmed]
PHST- 2018/10/30 06:00 [medline]
PST - epublish
SO  - Cell Mol Biol (Noisy-le-grand). 2018 Jul 30;64(10):102-107.